Results 81 to 90 of about 8,986 (182)

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review

New Microbes and New Infections
Background: Burkholderia cepacia complex (BCC) is a group of multi-drug resistant (MDR) pathogens that are challenging to treat, especially in cystic fibrosis (CF) patients.
Abolfazl Rafati Zomorodi, Leila Ghanbari_Afra, Hossein Faridafshar, Seyed Nooreddin Faraji, Fatemeh Zarepour, Maryamosadat Mavaei, Mohammad Rahmanian   +6 more
doaj   +1 more source

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies

Diagnostic Microbiology and Infectious Disease
We described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω-loop.
Amadesi S., Amedeo A., Rinaldi M., Palombo M., Giannella M., Gaibani P.   +5 more
openaire   +2 more sources

Ceftazidime/avibactam for specified infections [PDF]

Australian Prescriber, 2020
openaire   +2 more sources

The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting

Journal of Global Antimicrobial Resistance
BACKGROUND: Ceftazidime-avibactam (CZA) represents a novel therapeutic approach for combating infections caused by multidrug-resistant Gram-negative bacteria. With the rise of antimicrobial resistance posing a significant challenge in hospital settings, this study aims to evaluate the utilization of CZA in hospitals and its subsequent outcomes. METHODS:
Shobana Selvaganesan, Dorairajan Suresh Kumar, Rithik Dharan   +2 more
openaire   +2 more sources

Effectiveness of Ceftazidime/Avibactam treatment for infections caused by Klebsiella pneumoniae Carbapenemase (KPC), a 30-day mortality perspective. Comparison of results with control groups treated with other antibiotics

Journal of Education, Health and Sport
Introduction: Infections caused by Klebsiella pneumoniae carbapenemase (KPC) pose a significant clinical challenge due to increasing antibiotic resistance.
Patrycja Paschke, Igor Miczek, Maria Sambura, Sara Rosołowska-Żak, Julia Pałuchowska, Anna Szymkowicz   +5 more
doaj   +1 more source

Ceftazidime-avibactam susceptibility against Escherichia coli and Klebsiella pneumoniae

Iranian Journal of Microbiology
Background and Objectives: Carbapenem-resistant Enterobacteriaceae (CRE) infections are extremely difficult to treat and have a high fatality rate. The study's primary goal was to determine the rate of ceftazidime-avibactam susceptibility using disc diffusion and E-Test, as well as to evaluate the agreement between the two methods.
Arun Sachu, Alice David
openaire   +3 more sources

Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration

Pharmacology Research & Perspectives
Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in ...
Michael Thy, Alexandre Debs, Gabrielle Lui, Leo Froelicher‐Bournaud, Jean‐Marc Tréluyer, Mehdi Oualha   +5 more
doaj   +1 more source

Allergy to ceftazidime/avibactam: diagnosis and desensitization

Advances in Dermatology and Allergology
Cristallo, Mattia, Chaoul, Nada, Albanesi, Marcello, Nettis, Eustachio, Di Girolamo, Attilio   +4 more
openaire   +2 more sources

Severe hypokalemia induced by ceftazidime-avibactam: Case report. [PDF]

Medicine (Baltimore)
Yuan Y, Gu Y, Bai W, Liu W, Li W, Yin Y.
europepmc   +1 more source